DAVENPORT & Co LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY

DAVENPORT & Co LLC purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 1,759 shares of the biopharmaceutical company’s stock, valued at approximately $699,000.

Several other large investors have also made changes to their positions in ALNY. OFI Invest Asset Management grew its position in shares of Alnylam Pharmaceuticals by 5.8% during the third quarter. OFI Invest Asset Management now owns 403 shares of the biopharmaceutical company’s stock worth $184,000 after purchasing an additional 22 shares in the last quarter. Howard Capital Management Inc. lifted its holdings in Alnylam Pharmaceuticals by 2.9% in the 3rd quarter. Howard Capital Management Inc. now owns 854 shares of the biopharmaceutical company’s stock worth $389,000 after purchasing an additional 24 shares in the last quarter. Frank Rimerman Advisors LLC lifted its holdings in Alnylam Pharmaceuticals by 2.0% in the 3rd quarter. Frank Rimerman Advisors LLC now owns 1,251 shares of the biopharmaceutical company’s stock worth $570,000 after purchasing an additional 24 shares in the last quarter. Coastal Bridge Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 2.3% in the 3rd quarter. Coastal Bridge Advisors LLC now owns 1,097 shares of the biopharmaceutical company’s stock worth $500,000 after purchasing an additional 25 shares during the period. Finally, Meridian Financial Advisors LLC boosted its stake in Alnylam Pharmaceuticals by 3.5% in the 3rd quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company’s stock worth $378,000 after purchasing an additional 28 shares during the period. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 9,577 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.86, for a total value of $3,475,110.22. Following the completion of the transaction, the chief executive officer directly owned 78,411 shares of the company’s stock, valued at $28,452,215.46. This trade represents a 10.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Jeffrey V. Poulton sold 2,780 shares of the business’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.87, for a total transaction of $1,008,778.60. Following the completion of the sale, the executive vice president owned 57,465 shares in the company, valued at approximately $20,852,324.55. This trade represents a 4.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 53,923 shares of company stock worth $18,072,087 over the last three months. 1.20% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Stock Down 0.4%

Shares of ALNY opened at $316.09 on Tuesday. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. The stock has a market capitalization of $41.92 billion, a price-to-earnings ratio of 184.85 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The business’s 50 day simple moving average is $329.81 and its 200-day simple moving average is $398.61.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. During the same period last year, the business posted ($0.65) earnings per share. The company’s revenue for the quarter was up 84.9% compared to the same quarter last year. As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ALNY. Bank of America reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 12th. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Thursday, January 15th. Wall Street Zen cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, March 21st. Needham & Company LLC reduced their price target on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Finally, Stifel Nicolaus boosted their price target on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $473.87.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.